These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 24980949)
21. Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential. Entwistle J; Brown JG; Chooniedass S; Cizeau J; MacDonald GC Cancer Biother Radiopharm; 2012 Nov; 27(9):582-92. PubMed ID: 22856424 [TBL] [Abstract][Full Text] [Related]
22. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Rao CG; Chianese D; Doyle GV; Miller MC; Russell T; Sanders RA; Terstappen LW Int J Oncol; 2005 Jul; 27(1):49-57. PubMed ID: 15942643 [TBL] [Abstract][Full Text] [Related]
23. Detection of circulating tumor-associated antigen depends on the domains recognized by the monoclonal antibodies used: N-terminal trimmed EpCAM-levels are much higher than untrimmed forms. Schmetzer O; Moldenhauer G; Nicolaou A; Schlag P; Riesenberg R; Pezzutto A Immunol Lett; 2012 Apr; 143(2):184-92. PubMed ID: 22387297 [TBL] [Abstract][Full Text] [Related]
24. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Patriarca C; Macchi RM; Marschner AK; Mellstedt H Cancer Treat Rev; 2012 Feb; 38(1):68-75. PubMed ID: 21576002 [TBL] [Abstract][Full Text] [Related]
25. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009 [TBL] [Abstract][Full Text] [Related]
26. The use of sensitive chemical antibodies for diagnosis: detection of low levels of EpCAM in breast cancer. Shigdar S; Qian C; Lv L; Pu C; Li Y; Li L; Marappan M; Lin J; Wang L; Duan W PLoS One; 2013; 8(2):e57613. PubMed ID: 23460885 [TBL] [Abstract][Full Text] [Related]
28. Analysis of the specificity and selectivity of anti-EpCAM antibodies in breast cancer cell lines. Sterzynska K; Kempisty B; Zawierucha P; Zabel M Folia Histochem Cytobiol; 2012; 50(4):534-41. PubMed ID: 23264216 [TBL] [Abstract][Full Text] [Related]
29. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody. Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649 [TBL] [Abstract][Full Text] [Related]
30. Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy. Das M; Sahoo SK Acta Biomater; 2011 Jan; 7(1):355-69. PubMed ID: 20727991 [TBL] [Abstract][Full Text] [Related]
31. Production of novel recombinant anti-EpCAM antibody as targeted therapy for breast cancer. Mirzaei R; Shafiee S; Vafaei R; Salehi M; Jalili N; Nazerian Z; Muhammadnajad A; Yadegari F; Reza Esmailinejad M; Farahmand L Int Immunopharmacol; 2023 Sep; 122():110656. PubMed ID: 37473710 [TBL] [Abstract][Full Text] [Related]
32. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Trzpis M; McLaughlin PM; de Leij LM; Harmsen MC Am J Pathol; 2007 Aug; 171(2):386-95. PubMed ID: 17600130 [TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells. Schanzer JM; Fichtner I; Baeuerle PA; Kufer P J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804 [TBL] [Abstract][Full Text] [Related]
34. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL. Hussain S; Plückthun A; Allen TM; Zangemeister-Wittke U Mol Cancer Ther; 2006 Dec; 5(12):3170-80. PubMed ID: 17172421 [TBL] [Abstract][Full Text] [Related]
35. EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus. Kawashima R; Abei M; Fukuda K; Nakamura K; Murata T; Wakayama M; Seo E; Hasegawa N; Mizuguchi H; Obata Y; Hyodo I; Hamada H; Yokoyama KK Int J Cancer; 2011 Sep; 129(5):1244-53. PubMed ID: 21710497 [TBL] [Abstract][Full Text] [Related]
36. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Münz M; Kieu C; Mack B; Schmitt B; Zeidler R; Gires O Oncogene; 2004 Jul; 23(34):5748-58. PubMed ID: 15195135 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans. Amann M; Friedrich M; Lutterbuese P; Vieser E; Lorenczewski G; Petersen L; Brischwein K; Kufer P; Kischel R; Baeuerle PA; Schlereth B Cancer Immunol Immunother; 2009 Jan; 58(1):95-109. PubMed ID: 18594818 [TBL] [Abstract][Full Text] [Related]
38. Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages. Hristodorov D; Mladenov R; Fischer R; Barth S; Thepen T Immunol Cell Biol; 2016 May; 94(5):470-8. PubMed ID: 26743033 [TBL] [Abstract][Full Text] [Related]
39. EpCAM (CD326) finding its role in cancer. Baeuerle PA; Gires O Br J Cancer; 2007 Feb; 96(3):417-23. PubMed ID: 17211480 [TBL] [Abstract][Full Text] [Related]
40. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Seligson DB; Pantuck AJ; Liu X; Huang Y; Horvath S; Bui MH; Han KR; Correa AJ; Eeva M; Tze S; Belldegrun AS; Figlin RA Clin Cancer Res; 2004 Apr; 10(8):2659-69. PubMed ID: 15102668 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]